- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Focus Articles
- Related Articles4 new
- Instablogs
- StockTalks
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
GSK Market Currents
more »
-
12:07 PM Human Genome (HGSI -2.4%) slips on a BMO downgrade to Market Perform. THe firm believes the risk of GlaxoSmithKline (GSK) dropping its offer has increased and the likelihood of an significant price increase or a contingent value right for darapladib has been reduced. The firm lowers its price target to $13 from $17.
Comment![Healthcare, On the Move]
- Wednesday 8:55 AM GSK (GSK) ammends the conditions of its $2.6B tender offer for Human Genome (HGSI), requiring that the latter redeem or invalidate its poison pill. [Healthcare, M&A]
- Monday 8:51 AM Auxilium (AUXL) and GSK plan to jointly sell Auxilium's testosterone gel, Testim, in the U.S. under a deal that will last till Sept. 2015. Also, Auxilium narrows its FY net loss forecast to $5M-$10M from previous guidance of $5M-$15M and raises its revenue forecast to $293M-$315M from $283M-$305M. Consensus is $299.2M. (PR) [Healthcare]
GSK in Focus
more »
GSK Related Articles
more »
GSK News
more »
-
at CNBC.com (May 17, 2012)
-
at CNBC.com (May 9, 2012)
-
at CNBC.com (May 9, 2012)
-
at CNBC.com (May 9, 2012)
-
at MarketWatch.com (Apr 25, 2012)
GSK Press Releases and Filings
more »
-
PR Newswire (Apr 26, 2012)
-
PR Newswire (Mar 20, 2012)
GSK Latest Transcript
more »
-
Wed, Apr 25
GSK Cramer
more »
-
Fri, Aug 12, 2011
-
Fri, Feb 18, 2011
-
Fri, Mar 19, 2010
GSK Instablog posts
more »
GSK vs. ETF Alternatives
Company Description
Currently, there's no company description for GSK.
